Expand SMMT Menu
SMMT MENU

SMMT Latest Press Releases

-- February 26, 2026 --

Summit Therapeutics to Present at Upcoming Investor Conferences Business Wire 6:45 PM

-- February 23, 2026 --

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 Business Wire 4:05 PM

-- February 17, 2026 --

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 Business Wire 5:05 PM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- January 30, 2026 --

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- January 29, 2026 --

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy Business Wire 7:30 AM

-- January 12, 2026 --

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) Business Wire 6:15 AM
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC Business Wire 6:00 AM

-- January 9, 2026 --

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 8:16 PM

-- January 6, 2026 --

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 7:30 AM

-- December 5, 2025 --

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- November 7, 2025 --

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China Business Wire 9:00 AM

-- November 4, 2025 --

Summit Therapeutics to Present at Upcoming Investor Conferences Business Wire 7:00 AM

-- October 31, 2025 --

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 Business Wire 7:00 AM

-- October 22, 2025 --

Summit Therapeutics Raises $500 Million in Private Placement Business Wire 8:00 AM

-- October 20, 2025 --

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 Business Wire 6:45 AM

-- October 19, 2025 --

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Business Wire 10:30 AM

-- October 18, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT PRNewswire 10:00 AM

-- October 17, 2025 --

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer Business Wire 7:00 AM

-- October 15, 2025 --

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 Business Wire 7:00 AM

-- October 13, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT PRNewswire 2:01 PM
Market Data Delayed 15 Minutes